Olanzapine

Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM) . Olanzapine is an atypical antipsychotic[1][2].

Product Specifications

CAS Number

[132539-06-1]

Product Name Alternative

LY170053

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

5-HT Receptor; Adrenergic Receptor; Apoptosis; Autophagy; Dopamine Receptor; mAChR; Mitophagy

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Olanzapine.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

CC1=CC(C(N2CCN(C)CC2)=N3)=C(S1)NC4=C3C=CC=C4

Molecular Formula

C17H20N4S

Molecular Weight

312.44

Precautions

H302, H315, H319, H335

References & Citations

[1]APPROVED AGREED-UPON LABELING.|[2]Olanzapine for Injection, powder, for solution for intramuscular use.|[3]Vucicevic L, et al. Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. Autophagy. 2014;10 (12) :2362-78.|[4]Karpel-Massler G, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. J Neurooncol. 2015 Mar;122 (1) :21-33.|[5]Coccurello R, et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mousemodel of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) . 2006 Jul;186 (4) :561-71.